CY1123059T1 - Αναστολη του διαυλου ιοντων παροδικου δυναμικου του υποδοχεα α1 - Google Patents

Αναστολη του διαυλου ιοντων παροδικου δυναμικου του υποδοχεα α1

Info

Publication number
CY1123059T1
CY1123059T1 CY20201100485T CY201100485T CY1123059T1 CY 1123059 T1 CY1123059 T1 CY 1123059T1 CY 20201100485 T CY20201100485 T CY 20201100485T CY 201100485 T CY201100485 T CY 201100485T CY 1123059 T1 CY1123059 T1 CY 1123059T1
Authority
CY
Cyprus
Prior art keywords
ion channel
channel inhibition
receptor
transient ion
receptor transient
Prior art date
Application number
CY20201100485T
Other languages
English (en)
Inventor
Bertand L. CHENARD
Xinyuan Wu
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of CY1123059T1 publication Critical patent/CY1123059T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Discharging, Photosensitive Material Shape In Electrophotography (AREA)
  • Electrotherapy Devices (AREA)
  • Oscillators With Electromechanical Resonators (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Η παρούσα εφεύρεση αναφέρεται σε φαρμακευτικές ενώσεις Τύπου (Ι) ή ένα φαρμακευτικά αποδεκτό άλας ή σύνθεση αυτών και σε μεθόδους χρήσης τους για την αγωγή του άλγους, αναπνευστικών παθήσεων καθώς επίσης και για την αναστολή του διαύλου ιόντων Παροδικού Δυναμικού του Υποδοχέα Α1 (TRPA1).
CY20201100485T 2014-09-19 2020-05-28 Αναστολη του διαυλου ιοντων παροδικου δυναμικου του υποδοχεα α1 CY1123059T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462052678P 2014-09-19 2014-09-19
PCT/US2015/051063 WO2016044792A1 (en) 2014-09-19 2015-09-18 Inhibiting the transient receptor potential a1 ion channel

Publications (1)

Publication Number Publication Date
CY1123059T1 true CY1123059T1 (el) 2021-10-29

Family

ID=54249631

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20201100485T CY1123059T1 (el) 2014-09-19 2020-05-28 Αναστολη του διαυλου ιοντων παροδικου δυναμικου του υποδοχεα α1

Country Status (18)

Country Link
US (2) US10221177B2 (el)
EP (1) EP3193880B1 (el)
JP (4) JP6571173B2 (el)
CN (1) CN106715430B (el)
AU (1) AU2015317332B2 (el)
CA (1) CA2961412C (el)
CY (1) CY1123059T1 (el)
DK (1) DK3193880T3 (el)
ES (1) ES2788395T3 (el)
HR (1) HRP20200601T1 (el)
HU (1) HUE049253T2 (el)
LT (1) LT3193880T (el)
PL (1) PL3193880T3 (el)
PT (1) PT3193880T (el)
RS (1) RS60192B1 (el)
SI (1) SI3193880T1 (el)
TW (1) TWI704149B (el)
WO (1) WO2016044792A1 (el)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI676626B (zh) * 2014-04-23 2019-11-11 美商美國禮來大藥廠 抑制瞬時受體電位ａ１離子通道
PL3193880T3 (pl) * 2014-09-19 2020-09-07 Eli Lilly And Company Hamowanie kanału jonowego receptora przejściowego potencjału A1
JP6511692B2 (ja) * 2015-05-20 2019-05-15 グアンドン レイノベント バイオテック カンパニー リミテッド ヒドロキシプリン類化合物及びその応用
CN107614501B (zh) 2015-05-20 2020-01-14 广东众生睿创生物科技有限公司 羟基嘌呤类化合物及其应用
TWI690529B (zh) * 2015-05-20 2020-04-11 大陸商廣東衆生睿創生物科技有限公司 羥基嘌呤類化合物及其應用
TWI690526B (zh) * 2015-05-20 2020-04-11 大陸商廣東衆生睿創生物科技有限公司 羥基嘌呤類化合物及其應用
EP3554500A1 (en) * 2016-12-16 2019-10-23 Galderma Research & Development Trpa1 antagonists for use in the treatment of atopic dermatitis
EP3746445A1 (en) * 2018-01-31 2020-12-09 Eli Lilly And Company Inhibiting the transient receptor potential a1 ion channel
CN114502540A (zh) 2019-05-31 2022-05-13 医肯纳肿瘤学公司 Tead抑制剂和其用途
US10582716B1 (en) 2019-06-14 2020-03-10 Lennham Pharmaceuticals, Inc. Deuterated caffeine and uses thereof
FR3114235A1 (fr) 2020-09-18 2022-03-25 Université Grenoble Alpes Inhibition du canal trpa1 astrocytaire comme nouvelle cible therapeutique neuroprotectrice dans les phases prodromales de la maladie d’alzheimer
IT202100015098A1 (it) 2021-06-09 2022-12-09 Flonext S R L Composto antagonista del canale trpa1 per uso in patologie degenerative della retina
KR20230027841A (ko) 2021-08-20 2023-02-28 주식회사 엘지에너지솔루션 충방전 전력 제어 장치, 에너지 저장 시스템 및 에너지 저장 시스템의 동작 방법
WO2023133502A1 (en) * 2022-01-07 2023-07-13 The Johns Hopkins University Treatment and prevention of trigeminal neuralgia
CN114671876B (zh) * 2022-04-27 2023-10-03 成都施贝康生物医药科技有限公司 新型茶碱类化合物、异构体或盐及其制备方法和用途
CN116655635B (zh) * 2023-05-19 2024-01-26 济南爱思医药科技有限公司 黑茶茶碱衍生物及在制备药物中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006327181A1 (en) 2005-12-22 2007-06-28 Hydra Biosciences, Inc. TRPA1 inhibitors for treating pain
SI3184527T1 (sl) * 2007-06-22 2020-03-31 Eli Lilly And Company Spojine 2,6-diokso,-2,3-dihidro-1H-purina uporabne za zdravljenje stanj povezanih z aktivnostjo TRPA1 kanala
WO2009140517A1 (en) 2008-05-14 2009-11-19 Hydra Biosciences, Inc. Compounds and compositions for treating chemical warfare agent-induced injuries
WO2010036821A1 (en) * 2008-09-24 2010-04-01 Hydra Biosciences, Inc. Methods and compositions for treating respiratory disorders
AR087501A1 (es) 2011-08-09 2014-03-26 Hydra Biosciences Inc Compuestos inhibidores del canal ionico del potencial receptor transitorio trpa1
TW201441225A (zh) 2013-01-18 2014-11-01 Cubist Pharm Inc 瞬時受體電位ａ１離子通道之抑制
GB201309333D0 (en) * 2013-05-23 2013-07-10 Agency Science Tech & Res Purine diones as WNT pathway modulators
TWI676626B (zh) 2014-04-23 2019-11-11 美商美國禮來大藥廠 抑制瞬時受體電位ａ１離子通道
PL3193880T3 (pl) * 2014-09-19 2020-09-07 Eli Lilly And Company Hamowanie kanału jonowego receptora przejściowego potencjału A1

Also Published As

Publication number Publication date
PT3193880T (pt) 2020-06-19
SI3193880T1 (sl) 2020-06-30
US10221177B2 (en) 2019-03-05
RS60192B1 (sr) 2020-06-30
CN106715430B (zh) 2019-09-17
WO2016044792A1 (en) 2016-03-24
JP6571173B2 (ja) 2019-09-04
DK3193880T3 (da) 2020-06-02
EP3193880A1 (en) 2017-07-26
JP2017528490A (ja) 2017-09-28
EP3193880B1 (en) 2020-03-25
JP2021120403A (ja) 2021-08-19
ES2788395T3 (es) 2020-10-21
LT3193880T (lt) 2020-05-11
HRP20200601T1 (hr) 2020-07-10
US20190330212A1 (en) 2019-10-31
JP2023015338A (ja) 2023-01-31
PL3193880T3 (pl) 2020-09-07
AU2015317332B2 (en) 2019-07-18
CA2961412A1 (en) 2016-03-24
AU2015317332A1 (en) 2017-03-16
CA2961412C (en) 2024-01-16
US20170275285A1 (en) 2017-09-28
HUE049253T2 (hu) 2020-09-28
JP7181967B2 (ja) 2022-12-01
TWI704149B (zh) 2020-09-11
US10519158B2 (en) 2019-12-31
CN106715430A (zh) 2017-05-24
TW201625619A (zh) 2016-07-16
JP2019206577A (ja) 2019-12-05

Similar Documents

Publication Publication Date Title
CY1123059T1 (el) Αναστολη του διαυλου ιοντων παροδικου δυναμικου του υποδοχεα α1
CY1124243T1 (el) Αναστολη του ιοντικου διαυλου υποδοχεα παροδικου δυναμικου α1
CY1123595T1 (el) Παραγωγα χολικου οξεος ως αγωνιστες fxr/tgr5
PH12018500041A1 (en) Substituted aza compoounds as irak-4 inhibitors
CY1118379T1 (el) Αναστολεις ιου ηπατιτιδας c
BR112018005497A2 (pt) compostos heterocíclicos e usos dos mesmos
SG10201811384TA (en) Mnk inhibitors and methods related thereto
EA201791420A1 (ru) Соединения триазолопиримидина и их применения
EA201650031A1 (ru) Производные пирролидин-2,5-диона, фармацевтические композиции и способы применения в качестве ингибиторов ido1
EA201891063A1 (ru) Производные дигидроимидазопиразинона, применимые в лечении рака
EA201691803A1 (ru) Ингибиторы калликреина плазмы человека
EA201692114A1 (ru) Замещенные дигидроизохинолиноновые соединения
SV2017005381A (es) Compuestos de imidazopiridazina
EA201600337A1 (ru) 2,6-замещенные пуриновые производные и их применение в лечении пролиферативных заболеваний
EA201692481A1 (ru) Комбинация, содержащая глюкокортикоид и edo-s101
CY1124251T1 (el) Παραγωγα καρβοξαμιδιου
CY1122077T1 (el) Νεα δακτυλιωμενα φαινοξυακεταμιδια
EA202091604A1 (ru) Ингибирование ионного канала a1 с транзиторным рецепторным потенциалом
EA201792425A1 (ru) Трициклические соединения и их применение в качестве ингибиторов фосфодиэстераз
CY1121063T1 (el) Αναστολεις της συνθασης της αλδοστερονης
EA202090414A1 (ru) Соединения и их применение
EA201790830A1 (ru) Ингибиторы альдостеронсинтазы
EA201791432A1 (ru) Композиции на основе пролекарства монометилфумарата
EA201792264A1 (ru) Способы лечения воспалительных заболеваний
EA201790632A1 (ru) 4'-винилзамещенные производные нуклеозидов в качестве ингибиторов репликации рнк респираторно-синцитиального вируса